---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-059049"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:33:38.368218+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics appoints Robert Lisicki to Board of Directors

## Summary
- Robert Lisicki appointed as Class II director effective July 23, 2023; Board expanded from four to five seats.
- Lisicki brings over 25 years pharma experience, including CCO at Arena Pharmaceuticals through its $6.7B sale to Pfizer.
- He will receive $35,000 annual fee and 75,000 stock options vesting 1/3 on Aug 1, 2024 then monthly over 24 months.
- Lisicki also joins Compensation and Nominating/Governance Committees.

## SEC filing metadata
- accession: 0001213900-23-059049
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390023059049/0001213900-23-059049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390023059049/ea182217-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-059049
- JSON: https://secwatch.observer/filing/0001213900-23-059049.json
- Plain text: https://secwatch.observer/filing/0001213900-23-059049.txt

## Key facts
- Executive change
  Robert Lisicki was appointed as Class II Director at Cadrenal Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: appointed Robert Lisicki to serve as a Class II director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023059049/0001213900-23-059049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.